Quarterly ResultMay 12, 2026, 09:02 AM
Connect Biopharma Phase 2 Studies On Track; $20.2M Private Placement Closed
AI Summary
Connect Biopharma reported Q1 2026 financial results and provided a business update, confirming its Phase 2 Seabreeze STAT studies for asthma and COPD are continuing as planned following a positive independent DMC review. The company anticipates topline data from these studies mid-2026 and plans to engage with the FDA for a Phase 3 program. Connect Biopharma also successfully closed a $20.2 million private placement financing, extending its cash runway into the second half of 2027, despite reporting an increased net loss of $19.4 million for the quarter.
Key Highlights
- Phase 2 Seabreeze STAT studies for asthma and COPD are continuing as planned.
- Topline data from both Phase 2 Seabreeze STAT studies are expected mid-2026.
- Connect Biopharma closed a $20.2 million private placement financing on March 31, 2026.
- Cash and cash equivalents were $46.0 million as of March 31, 2026.
- Cash and investments are expected to fund operations into the second half of 2027.
- Net loss for Q1 2026 was $19.4 million, or ($0.34) per share.
- Research and development expense increased to $15.0 million in Q1 2026 from $6.6 million in Q1 2025.
- Eligible for up to $110 million in remaining milestone payments from Simcere partnership.